M&A Deal Summary

Takeda Acquires Adaptate

On January 10, 2022, Takeda acquired life science company Adaptate

Acquisition Highlights
  • This is Takeda’s 15th transaction in the Life Science sector.
  • This is Takeda’s 3rd transaction in the United Kingdom.

M&A Deal Summary
Date 2022-01-10
Target Adaptate
Sector Life Science
Buyer(s) Takeda
Deal Type Add-on Acquisition

Target

Adaptate

London, United Kingdom
website
Adaptate develops antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells. Adaptate was founded in 2019 and is based in London, England.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takeda

Tokyo, Japan

website

Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4,027.5B JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 16 of 18
Sector (Life Science) 15 of 17
Type (Add-on Acquisition) 15 of 15
Country (United Kingdom) 3 of 3
Year (2022) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-27 GammaDelta

London, United Kingdom

GammaDelta is a clinically-staged biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer. Committed to transforming the treatment of patients living with cancer, the Company is developing an ‘off-the-shelf’ therapy based on one of the body’s own immune cells, a subtype of the gamma delta (γδ) T-lymphocyte, known as the Vδ1+ T cell. GammaDelta was founded in 2016 and is based in London, England.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-13 Nimbus Lakshmi

Cambridge, Massachusetts, United States

Nimbus Lakshmi is a clinical-stage company that designs and develops breakthrough medicines. Nimbus Lakshmi is based in Cambridge, Massachusetts.

Buy -
Mergr

Product

Company

Legal